Please try another search
On Wednesday, Argus made a significant adjustment to its rating on shares of Moderna Inc . (NASDAQ:BMV:MRNA), shifting from "Buy" to "Hold." The decision reflects a reassessment of the...
Moderna , Inc. (NASDAQ:MRNA), the biotechnology company that rose to prominence with its COVID-19 vaccine, is navigating a critical transition period as it seeks to diversify its product portfolio...
CAMBRIDGE, MA—Shannon Thyme Klinger, the Chief Legal Officer of Moderna , Inc. (NASDAQ:MRNA), sold 529 shares of the company's common stock on December 9, 2024. The shares were sold at an...
Shannon Thyme Klinger, Chief Legal Officer at Moderna , Inc. (NASDAQ:MRNA), reported a recent stock transaction involving the sale of company shares. On December 3, Klinger sold 112 shares of...
CAMBRIDGE, MA—Stephen Hoge, President of Moderna , Inc. (NASDAQ:MRNA), recently executed stock transactions as detailed in a Form 4 filing with the SEC. On December 3, Hoge sold 314 shares...
On Tuesday, Leerink Partners maintained their Underperform rating on Moderna (NASDAQ:MRNA), currently trading at $44.26, with a steadfast price target of $31.00. According to InvestingPro data,...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review